IMRN
Companies
NASDAQ
Immuron Ltd Sponsored ADR
Health Care
$1.72
+$0.14 (+8.24%)
Price Chart
Overview
About IMRN
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Market Cap
$12.7M
Volume
43.3K
Avg. Volume
20.2K
P/E Ratio
-168
Dividend Yield
0.00%
Employees
8.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.73
Low Correlation
Volatility
High (0.89)
Relative to market
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IMRN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$12.7M
Volume43.3K
P/E Ratio-168.00
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
August 31, 2021Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025